Hormone Replacement Therapy with Premarin and Provera

Introduction to Hormone Replacement Therapy

• The U.S. Preventive Services Task Force gives a Grade D recommendation for using oral Premarin 0.625 mg and oral Provera 10 mg for primary prevention of chronic conditions in postmenopausal women, due to harms outweighing benefits 1, 2

Indications and Contraindications

• The American College of Physicians and other guideline societies imply that this regimen is acceptable for menopausal symptom relief, which falls outside the USPSTF recommendation scope 1, 2
• The U.S. Preventive Services Task Force recommends against using this regimen for primary prevention of chronic conditions, with a Grade D recommendation 1, 2

Cardiovascular Risk

• For women with cardiovascular risk factors, consider using micronized progesterone instead of medroxyprogesterone acetate, as it may have a more favorable cardiovascular profile 3

Documented Harms and Benefits

• The Women's Health Initiative trial found increased risks of coronary heart disease, strokes, pulmonary embolisms, invasive breast cancers, dementia, gallbladder disease, and urinary incontinence, as well as decreased risks of colorectal cancers and hip fractures, associated with this regimen 1, 2

Age-Specific Considerations

• The American Heart Association/American Stroke Association guidelines state that women ≥60 years or >10 years post-menopause have elevated stroke risk with oral estrogen-containing HRT, but this patient at age 50 falls into a lower-risk category 4

Pre-Treatment Requirements

• Blood pressure measurement is required before initiation, and ensure the patient is not pregnant if there is any uncertainty 3

Monitoring and Duration

• If withdrawal bleeding does not occur within 3 weeks, pregnancy testing is advised 3